Skip to content

Camba-Pharma

Active Risk: not assessed
Private limited companyfounded 2019active for 7 yearsDroogveldeweg 7, 9031 Gent, BelgiumKBO/BCE: BE 0717.740.414

From the official registers: KBO 7 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

Camba-Pharma has a registered holding activity and consists mainly of financial fixed assets; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €137,100 and a net result of €47,651. Equity is growing by about 40% per year across the filed financial years. Its solvency ranks better than 48% of 22,679 sector peers (NACE 47, financial year 2025). The company has been active since 2019 and the Belgian Official Gazette contains no insolvency or warning signals.

Overview

Official details

KBO
Status
Active since 07-01-2019 Normal situation
Legal form
Private limited company
Registered office
Droogveldeweg 7, 9031 Gent
Activity
Retail sale of pharmaceutical products NACE 47730and 1 other
Establishment unit
2.283.517.976 9031 Gent, since 09-01-2019
Financial year end
31 December
Peppol
Reachable since 24-11-2023

Who decides

Board
Holdings
Shares in 1 company BIOCLIN

How it is doing

Holding: outside the score modelBankruptcy probability: sector outside the model
Annual accounts 2025
Gross margin
€69,398
▲ 21.6%
Turnover
≈ €340,000
estimated
Profit
€47,651
▲ 28.9%
Equity
€137,100
▲ 31.3%
Total assets
€437,825
▼ 4.1%
2025 accounts 114 days early
Filed on 08-04-2026PDF
SignalsneutralLatest accounts filed on timeShow the evidence

Checked score

Outside the general model
Holding: general score not applicable
The company has a registered holding activity and financial fixed assets account for more than half of its assets. The general operating-company model is unsuitable for this profile, so we show no financial axes either. Filed figures remain available.
Bankruptcy probability, 12 months

This is a financial institution (bank, insurer or financial holding). A bank balance sheet works differently from that of an ordinary trading or manufacturing company. We therefore show no bankruptcy probability rather than a misleading figure.

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

1 signal.
neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 08-04-2026, 114 days ahead of the deadline.
NBB · 7 filings
Deviation from the deadline
2025
114 days early
2024
13 days early
2023
12 days early
2022
29 days early
2021
26 days early
2020
46 days early
2019
31 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 30 days before the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 5 July (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
01-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage

Financials · financial year 2025, micro format

Latest annual accounts filed

Annual accounts 2025

Download PDF
Financial year ended
31-12-2025
Filed on
08-04-2026
Format
micro format
Reference
2026-00076156
Turnover
≈ €340,000
Estimated: probably between €180,000 and €460,000
Total assets
€437,825▼ 4.1%
2024 · €456,352
Net result
€47,651▲ 28.9%
2024 · €36,955
Working capital
-€80,554▼ 17.7%
2024 · -€68,461
Trend over the years

2021 to 2025, 5 financial years 2019 to 2025, 7 financial years

After the dip in 2023 the operating result has climbed two years in a row; 2025 is 22% above 2024 and is the highest result in the available series.

What the company sold each financial year and what was left of it. A loss stands below the zero line.

Operating result€68,885 2025 Net result€47,651 2025

Use the arrow keys on the chart for the figures per year.

Sector: the middle half of NACE 47, Retail trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).

Every figure with its change against the financial year before
favourable unfavourable
Line2019202020212022202320242025
Operating result€5,320-€31,266▲ 488%€32,745▲ 4.7%€49,945▲ 52.5%€48,873▼ 2.1%€56,550▲ 15.7%€68,885▲ 21.8%
Net result€2,720-€19,885within the sector's middle half▲ 631%€20,240within the sector's middle half▲ 1.8%€31,841above the sector's middle half▲ 57.3%€32,054above the sector's middle half▲ 0.7%€36,955above the sector's middle half▲ 15.3%€47,651above the sector's middle half▲ 28.9%
Equity€8,108-€27,193within the sector's middle half▲ 235%€59,833within the sector's middle half▲ 120%€50,441within the sector's middle half▼ 15.7%€67,494within the sector's middle half▲ 33.8%€104,449within the sector's middle half▲ 54.8%€137,100above the sector's middle half▲ 31.3%
Total assets€15,493-€244,805within the sector's middle half▲ 16×€265,702within the sector's middle half▲ 8.5%€458,890above the sector's middle half▲ 72.7%€457,640above the sector's middle half▼ 0.3%€456,352above the sector's middle half▼ 0.3%€437,825above the sector's middle half▼ 4.1%
Debt€7,385-€217,611▲ 29×€205,869▼ 5.4%€408,449▲ 98.4%€390,145▼ 4.5%€351,903▼ 9.8%€300,724▼ 14.5%
Working capital€5,270--€10,373below the sector's middle half€5,962within the sector's middle half-€53,579below the sector's middle half-€74,019below the sector's middle half▼ 38.2%-€68,461below the sector's middle half▲ 7.5%-€80,554below the sector's middle half▼ 17.7%
Solvency52.3%-11.1%within the sector's middle half▼ 41.2pp22.5%within the sector's middle half▲ 11.4pp11.0%within the sector's middle half▼ 11.5pp14.7%within the sector's middle half▲ 3.8pp22.9%within the sector's middle half▲ 8.1pp31.3%within the sector's middle half▲ 8.4pp
Current ratio1.76-0.72below the sector's middle half▼ 1.041.14within the sector's middle half▲ 0.420.33below the sector's middle half▼ 0.810.26below the sector's middle half▼ 0.070.27below the sector's middle half▲ 0.010.08below the sector's middle half▼ 0.19
Return on assets (ROA)17.6%-8.1%within the sector's middle half▼ 9.4pp7.6%within the sector's middle half▼ 0.5pp6.9%within the sector's middle half▼ 0.7pp7.0%within the sector's middle half▲ 0.1pp8.1%within the sector's middle half▲ 1.1pp10.9%within the sector's middle half▲ 2.8pp
above within below the middle half of NACE 47, Retail trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Turnover and EBIT margin not published: the micro format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €437,825
Fixed assets €431,108 ▼ 0.1%
Current assets €6,717 ▼ 73.0%
Equity and liabilities €437,825
Equity €137,100 ▲ 31.3%
Debt €300,724 ▼ 14.5%
Debt's share of the balance-sheet total falls from 77.1% to 68.7%. Equity is higher and debt is lower.
Key figures and ratios
2025 value · change against 2024
ROE
34.8%▼
2024 · 35.4%
Debt ≤ 1 year
€87,271▼
2024 · €93,336
Debt > 1 year
€212,664▼
2024 · €251,488
Income taxes
€16,590▲
2024 · €13,922
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 47 lines

Source: Annual accounts 2025 (PDF), filed with the National Bank on 08-04-2026.

Balance sheet Code20242025
Assets
Total assets20/58€456,352€437,825▼
Fixed assets21/28€431,477€431,108▼
Tangible fixed assets22/27€1,477€1,108▼
Furniture and vehicles24€1,477€1,108▼
Financial fixed assets28€430,000€430,000=
Current assets29/58€24,875€6,717▼
Amounts receivable within one year40/41€19,264-
Trade receivables40€19,264-
Cash at bank and in hand54/58€5,527€6,440▲
Deferred charges and accrued income490/1€85€277▲
Equity and liabilities
Total equity and liabilities10/49€456,352€437,825▼
Equity10/15€104,449€137,100▲
Contributions10/11€18,600€18,600=
Reserves13€85,849€118,500▲
Distributable reserves133€85,849€118,500▲
Amounts payable17/49€351,903€300,724▼
Amounts payable after more than one year17€251,488€212,664▼
Financial debts170/4€251,488€212,664▼
Amounts payable within one year42/48€93,336€87,271▼
Current portion of amounts payable after more than one year42€41,492€42,037▲
Financial debts43€3,884€4,890▲
Other loans439€3,884€4,890▲
Trade debts44€321€8,850▲
Suppliers440/4€321€8,850▲
Advances received on contracts in progress46€22,385-
Taxes, remuneration and social security45€7,686€11,626▲
Taxes450/3€7,686€11,626▲
Other amounts payable47/48€17,568€19,868▲
Accrued charges and deferred income492/3€7,078€790▼
Income statement Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€369€369=
Other operating charges640/8€141€144▲
Gross operating margin9900€57,060€69,398▲
Operating profit (loss)9901€56,550€68,885▲
Financial income75/76B€82€2▼
Recurring financial income75€82€2▼
Financial charges65/66B€5,756€4,646▼
Recurring financial charges65€5,756€4,646▼
Profit (loss) for the period before taxes9903€50,877€64,241▲
Income taxes67/77€13,922€16,590▲
Profit (loss) for the period9904€36,955€47,651▲
Profit (loss) for the period to be appropriated9905€36,955€47,651▲
Appropriation of the result
Profit (loss) to be appropriated9906€36,955€47,651▲
Transfer from equity791/2-€15,000
Transfer to equity691/2€36,955€47,651▲
To other reserves6921€36,955€47,651▲
Profit to be distributed694/7-€15,000
Return on contributions (dividend)694-€15,000

The notes to these accounts (6 items: statements of assets and debts, cost breakdowns, rights and commitments) are in the filed accounts (PDF).

Line2019202020212022202320242025Change
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€1,392€369€369€369€369€369€369=
Other operating charges640/8--€120€122€132€141€144▲ 2.6%
Gross operating margin9900€6,711€31,635€33,234€50,436€49,374€57,060€69,398▲ 21.6%
Operating profit (loss)9901€5,320€31,266€32,745€49,945€48,873€56,550€68,885▲ 21.8%
Financial income75/76B--€133€643€3€82€2▼ 97.6%
Recurring financial income75€0-€133€643€3€82€2▼ 97.6%
Financial charges65/66B--€2,826€5,004€5,247€5,756€4,646▼ 19.3%
Recurring financial charges65€415€2,816€2,826€5,004€5,247€5,756€4,646▼ 19.3%
Profit (loss) for the period before taxes9903€4,904€28,450€30,052€45,585€43,629€50,877€64,241▲ 26.3%
Income taxes67/77€2,184€8,565€9,812€13,744€11,576€13,922€16,590▲ 19.2%
Profit (loss) for the period9904€2,720€19,885€20,240€31,841€32,054€36,955€47,651▲ 28.9%
Profit (loss) for the period to be appropriated9905€2,720€19,885€20,240€31,841€32,054€36,955€47,651▲ 28.9%
Line2019202020212022202320242025Change
Assets
Total assets20/58€15,493€244,805€265,702€458,890€457,640€456,352€437,825▼ 4.1%
Fixed assets21/28€3,323€217,954€217,585€432,215€431,846€431,477€431,108▼ 0.1%
Tangible fixed assets22/27€3,323€2,954€2,585€2,215€1,846€1,477€1,108▼ 25.0%
Furniture and vehicles24--€2,585€2,215€1,846€1,477€1,108▼ 25.0%
Financial fixed assets28-€215,000€215,000€430,000€430,000€430,000€430,000=
Current assets29/58€12,170€26,851€48,117€26,675€25,794€24,875€6,717▼ 73.0%
Amounts receivable within one year40/41€7,287€15,175€26,153€21,856€11,322€19,264--
Trade receivables40--€6,397€21,856€10,783€19,264--
Other amounts receivable41--€19,756-€538---
Cash at bank and in hand54/58€4,042€11,209€20,848€3,901€14,216€5,527€6,440▲ 16.5%
Deferred charges and accrued income490/1--€1,116€918€257€85€277▲ 227%
Equity and liabilities
Total equity and liabilities10/49€15,493€244,805€265,702€458,890€457,640€456,352€437,825▼ 4.1%
Equity10/15€8,108€27,193€59,833€50,441€67,494€104,449€137,100▲ 31.3%
Contributions10/11€6,200-€18,600€18,600€18,600€18,600€18,600=
Reserves13€1,908€20,993€41,233€31,841€48,894€85,849€118,500▲ 38.0%
Distributable reserves133--€41,233€31,841€48,894€85,849€118,500▲ 38.0%
Amounts payable17/49€7,385€217,611€205,869€408,449€390,145€351,903€300,724▼ 14.5%
Amounts payable after more than one year17-€180,107€163,482€327,634€289,809€251,488€212,664▼ 15.4%
Financial debts170/4--€163,482€327,634€289,809€251,488€212,664▼ 15.4%
Amounts payable within one year42/48€6,900€37,224€42,155€80,253€99,813€93,336€87,271▼ 6.5%
Current portion of amounts payable after more than one year42--€18,000€40,424€40,955€41,492€42,037▲ 1.3%
Financial debts43---€5,853€2,706€3,884€4,890▲ 25.9%
Other loans439---€5,853€2,706€3,884€4,890▲ 25.9%
Trade debts44€2,217€1,618€189€996€373€321€8,850▲ 28×
Suppliers440/4--€189€996€373€321€8,850▲ 28×
Advances received on contracts in progress46-----€22,385--
Taxes, remuneration and social security45--€23,897€23,255€18,799€7,686€11,626▲ 51.3%
Taxes450/3--€23,897€19,727€13,255€7,686€11,626▲ 51.3%
Remuneration and social security454/9---€3,528€5,544---
Other amounts payable47/48--€69€9,726€36,981€17,568€19,868▲ 13.1%
Accrued charges and deferred income492/3--€232€562€523€7,078€790▼ 88.8%
Line2019202020212022202320242025Change
Profit (loss) for the period9904€2,720€19,885€20,240€31,841€32,054€36,955€47,651▲ 28.9%
+ Depreciation and write-downs630€1,392€369€369€369€369€369€369=
Operating cash flow (approximation)€4,112€20,254€20,609€32,210€32,423€37,324€48,020▲ 28.7%
Investment in fixed assets (approximation)--€215,000€0-€215,000€0€0€0-
Change in cash-€7,167€9,639-€16,947€10,315-€8,689€913-

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Filings with the National Bank (7)
Financial year Type Filed Reference Document
31-12-2025 micro format 08-04-2026 2026-00076156 PDF
31-12-2024 micro format 18-07-2025 2025-00295780 PDF
31-12-2023 micro format 19-07-2024 2024-00270143 PDF
31-12-2022 micro format 02-07-2023 2023-00199051 PDF
31-12-2021 micro format 05-07-2022 2022-20150759 PDF
31-12-2020 micro format 15-06-2021 2021-20300459 PDF
31-12-2019 micro format 31-08-2020 2020-48900346 PDF

Similar companies · same sector, comparable size

Of the 5,203 active companies whose main activity is retail sale of pharmaceutical products (NACE 47730), figures are known for 3,907. 3,577 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector

Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.

Directors

Directors
1 director, last change in 2023
Camille BAETSLÉ
Director (not named in the articles) · since 07-01-2019 · in the 2025 annual accounts, filed on 08-04-2026
Current

Mandate history

1 person, 1 in office
Show
  • Board
  • began earlier
Mandates per person, with start and end dates
Name Functions and periods
Camille BAETSLÉ
  • Director, until 29-12-2023
  • Director (not named in the articles), appointed in the act of 29-12-2023, still in office
See the board, name and registered office on a given date →

How the board is organised

Who represents it, and how

Who signsWho may bind the company towards others, for example by signing a contract.
Each director alone
Board ruleHow the board is made up, meets and takes decisions.
“Bestuursorgaan, met of zonder beperking”
3 more provisions on this in the deed

Oversight and winding up

Dissolution ruleWhen and by whom the company can be dissolved.
“Ontbinding, aandeelhouders”
“Besluit algemene vergadering in vormen statutenwijziging”
1 more provision on this in the deed
Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
“Alle schulden naar evenredigheid zonder onderscheid opeisbaar en niet-opeisbaar onder aftrek disconto, opeisbare eerst op eigen risico…”

Articles of association, deed of 29-12-2023

Owners and capital

Capital and shareholders

Capital over the years
  1. 29-12-2023 Converted to unavailable equity · €18,600

Shares according to the articles of association

Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
“Overdracht geheel of gedeelte aandelen onder levenden, enige aandeelhouder alleen”
Other provisionsRules from the articles on subjects other than the board, the shares, the purpose and the meetings.
Other provision: “Aandelen moeten bij uitgifte worden volgestort, stortingsplicht aandelen”
Other provision: “Beraadslaging-aanwezigheidsquorum, wettelijke en statutaire bepalingen aandelen zonder stemrecht”
Other provision: “Controle, schadevergoeding”
Other provision: “Winstverdeling en uitkeringen, algemene vergadering op voorstel bestuursorgaan”
Liquidation distribution: “Aandeelhouders a rato aandelenbezit, blote eigenaars met last plaatsing op geblokkeerde bankrekening op naam blote eigenaars en…”
Other provision: “Dag verdeling aandelen of aflevering legaten, overlijden enige aandeelhouder met erf-gerechtigden”
12 more provisions in the deed, see the deed of 29-12-2023

Articles of association, deed of 29-12-2023 (in Dutch)

Group and network

Holdings and subsidiaries

1 holding

Holdings 1

Connections & network

1 current director
Depth

The board mandates are listed below; here you explore them as a network.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.

Board mandates elsewhere

1 board mandate
Board mandates of this companythis company sits on their board1
1 location

History

Camba-Pharma was incorporated on 7 January 2019.1 The registered office was moved to Drongen in 2023.2 Total assets rose from €15,493 in 2019 to €437,825 in 2025.3

  1. 1KBO register
  2. 2Belgian Official Gazette, 03-01-2023
  3. 3National Bank, annual accounts 2019 and 2025

Acts, filings and financial milestones

Next filing, financial year 2026, expected by 31-07-2027
2026
08-04
NBB filing Annual accounts filedPDF
financial year 2025 · micro format
2025
31-12
Financial Highest result from 2019 to 2025net €47,651 ▲28.9%
Operating result €68,885, net result €47,651, both a record.
18-07
NBB filing Annual accounts filedPDF
financial year 2024 · micro format
2024
31-12
Financial Equity above €100,000equity €104,449 ▲54.8%
A profit in every financial year since 2019 builds equity to €104,449.
19-07
NBB filing Annual accounts filedPDF
financial year 2023 · micro format
2023
29-12
Gazette deed Resignation: Camille BAETSLÉ (director)
Appointment: Camille BAETSLÉ (director) · Amendment of the articles · Capital conversion9 facts ▸
  • General meeting, 21-12-2023
  • Amendment of the articles (2 times)
  • Capital conversion, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
  • Capital
  • Power of attorney, Jessica Verhaeghe
  • Director resignation, Camille BAETSLÉ (director)
  • Director appointment, Camille BAETSLÉ (director (not named in the articles))
  • Director discharge, Camille BAETSLÉ
  • Registered office clause, “Droogveldeweg 7, zevende besluit algemene vergadering” (deed in Dutch)

Open the act in the Belgian Official Gazette

02-07
NBB filing Annual accounts filedPDF
financial year 2022 · micro format
03-01
Gazette deed Registered office · Legal-form change
Registered-office move2 facts ▸
  • Board meeting, 01-09-2022
  • Registered-office move, Droogveldeweg 7,9031 Drongen

Open the act in the Belgian Official Gazette

2022
05-07
NBB filing Annual accounts filedPDF
financial year 2021 · micro format
2021
15-06
NBB filing Annual accounts filedPDF
financial year 2020 · micro format
2020
31-08
NBB filing Annual accounts filedPDF
financial year 2019 · micro format · 31 days late
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.

Sources:Publications in the Belgian Official GazetteFilings with the National Bank

Register details

Who it is

KBO record
Name Camba-Pharma in Dutch
Enterprise number 0717.740.414
Legal form Private limited company
Status Active, normale toestand
Founded 07-01-2019
Type Legal entity

Where it is based

Registered office Droogveldeweg 7, 9031 Gent, Belgium
Establishments 1 establishment unit since 2019

What it does

NACEBEL 2025
47730 Retail sale of pharmaceutical products main activity
64210 Activities of holding companies

Invoicing and payment

VAT number BE 0717.740.414
E-invoicing via Peppol
Reachable via Peppol
Peppol ID 0208:0717740414
Also 9925:BE0717740414
Registered 24-11-2023

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 31 October 2026 · Peppol Directory

Financial year and general meeting

Accounts at the NBB
Financial year end 31-12

Scores and ratios are computed by Checked and are not a credit decision.

Purpose, financial year and meetings according to the articles of association

What the company does

PurposeThe activities the company may carry out under its articles.
“Het verlenen van alle mogelijk advies en managementondersteuning voor de algemene uitbating van een apotheek; Het verlenen van…”
18 activities
  1. Het verlenen van alle mogelijk advies en managementondersteuning voor de algemene uitbating van een apotheek
  2. Het verlenen van dienstprestaties van economische aard in de farmaceutische sector,zowel in eigen beheer als in deelname met derden,daartoe behoren technoconsult,assistentie op gebied van management,engineering en consulting,technisch,commercieel,administratief en financieel beheer en advies,alsook het ter beschikking stellen en verhuren van dienstdoend apotheker en/of apotheekassistent(en)
  3. Het maken van alle farmaceutische,farmacologische en toxicologische studies en onderzoeken betreffende alle commerciële en industriële activiteiten,de organisatie van vennootschappen en ondernemingen,het verrichten van marktonderzoek,de promotie en het raad geven met betrekking tot industriële en commerciële projecten en alle werkzaamheden met betrekking tot de informatica
  4. De studie,verkoop en fabricage van voedingssupplementen,kruiden,sportproducten
  5. De invoer,de uitvoer,doorvoer,opslag en verkoop van bovenvermelde producten,evenals van grondstoffen en de moederlogen bestemd voor de bereiding van deze producten,alsook van planten,gewassen en etherische oliën,zonder dat deze opsomming beperkend weze
  6. De invoer,uitvoer,doorvoer,opslag en verkoop van alcolholhoudende dranken en van verscheidene fantasieartikelen,gecatalogeerd onder de benaming gadgets,zonder dat deze opsomming beperkend weze
  7. Het drukken en verspreiden van geschriften,studies en werken over bovenvermelde producten,en hun leer,fungeren als raadgevend bureau inzake industriële en commerciële activiteit die betrekking hebben op therapeutische middelen in hun meest uitgebreide toepassing
  8. Het beheren,het verwerven,de instandhouding en het valoriseren van een onroerend vermogen,de huurfinanciering van onroerende goederen aan derden,alsmede alle handelingen die rechtstreeks of onrechtstreeks met dit doel in verband staan en die van aard zijn de opbrengst van de onroerende goederen te bevorderen,zoals het onderhoud,de ontwikkeling,de verfraaiing en de verhuring van deze goederen,alsmede zich borg stellen voor het goede verloop van verbintenissen door derde personen aangegaan die het genot zouden hebben van deze onroerende goederen
  9. Het verwerven,hetzij door inschrijving of aankoop van aandelen,obligaties,kasbons of andere roerende waarden,van welke vorm ook,van Belgische of buitenlandse bestaande of nog op te richten vennootschappen alsook het beheer van deze roerende waarden,dit alles enkel voor eigen rekening
  10. Het ontwikkelen,kopen,verkopen,beheer,in waarde stellen,in licentie nemen of geven van brevetten,octrooien,know-how en andere intellectuele rechten
  11. De aan-en verkoop,in-en uitvoer,commissiehandel en vertegenwoordiging van om het even welke goederen,in’t kort tussenpersoon in de handel
  12. Alle verrichtingen van commerciële,industriële,onroerende,roerende of financiële aard die rechtstreeks of onrechtstreeks met haar voorwerp verwant of verknocht zijn of de verwezenlijking ervan kunnen bevorderen
  13. Het uitvoeren van alle studies en onderzoek,het verrichten van marktonderzoek,promotie,raadgeving,prospectie,marketing,techno-consult,assistentie op gebied van management,engineering en consulting;technisch,commercieel,administratief,financieel,fiscaal en juridisch beheer en advies
  14. Het bevorderen van de oprichting van vennootschappen door inbreng,participatie of investering
  15. Het toestaan van leningen en kredietopeningen aan vennootschappen of particulieren onder om het even welke vorm;in dit kader kan zij zich ook borg stellen of haar aval verlenen,in de meest ruime zin,alle handels-en financiële operaties verrichten behalve die welke wettelijk voorbehouden zijn aan depositobanken,houders van deposito's op korte termijn,spaarbanken,hypotheekmaatschappijen en kapitalisatieondernemingen
  16. Alle verrichtingen en diensten,hetzij als makelaar,agent of welk danige hoedanigheid,inzake verzekeringen en herverzekeringen van alle aard,zowel voor natuurlijke als voor rechtspersonen
  17. Het optreden als tussenpersoon bij onderhandelingen voor gehele of gedeeltelijke overname van aandelen;in de meest ruime betekenis,het deelnemen aan emissieverrichtingen van aandelen en vastrentende waarden door intekening,waarborgplaatsing,verhandeling of anderszins,alsmede het verwezenlijken van om het even welke verrichtingen inzake portefeuille-of kapitaalsbestuur
  18. Het waarnemen van alle bestuursopdrachten in andere vennootschappen,het uitoefenen van mandaten en functies in alle ondernemingen

The full purpose is in the deed

DurationHow long the company exists; usually unlimited, so until it is dissolved.
Unlimited
Name clauseThe name the company operates under according to its articles.
CAMBA-PHARMA
Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
“Vlaamse Gewest”

Meetings and financial year

Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
In June at 20:00

Articles of association, deed of 29-12-2023 (in Dutch)

Environmental permits: No permit applications found in Flanders.

Sites & property

Registered office and establishments
registered office establishment The establishment unit on the map
2 companies at this address See who is registered here
1 establishment unit
Camba-Pharma
Droogveldeweg 7, 9031 GentRetail sale of pharmaceutical products
since 2019unit no. 2.283.517.976

Buildings and parcels at the address

Ground area
856 m²
Building footprint
156 m²
Building volume
688 m³
Parcel 44017C0131/00F000, Flanders · tallest building 7.0 m.
1 parcel
Flanders 1 (100%)
Cadastral parcel Region Area Buildings Height / floors
44017C0131/00F000 Flanders 856 m² 1 · 156 m² 7.0 m · 2